1	Many	_	JJ	_	_	3	NMOD	_	_
2	genetic	_	JJ	_	_	3	NMOD	_	_
3	lesions	_	NNS	_	_	4	VMOD	_	_
4	are	_	VBP	_	_	0	ROOT	_	_
5	known	_	VBN	_	_	4	VC	_	_
6	to	_	TO	_	_	5	VMOD	_	_
7	influence	_	VB	_	_	6	IM	_	_
8	gene	_	NN	_	_	9	NMOD	_	_
9	expression	_	NN	_	_	7	VMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	tumor	_	NN	_	_	13	NMOD	_	_
12	suppressor	_	NN	_	_	13	NMOD	_	_
13	genes	_	NNS	_	_	10	PMOD	_	_
14	.	_	.	_	_	4	P	_	_
		
1	Whereas	_	IN	_	_	13	VMOD	_	_
2	mutations	_	NNS	_	_	7	VMOD	_	_
3	and	_	CC	_	_	2	COORD	_	_
4	deletions	_	NNS	_	_	3	CONJ	_	_
5	or	_	CC	_	_	4	COORD	_	_
6	insertions	_	NNS	_	_	5	CONJ	_	_
7	have	_	VBP	_	_	1	SUB	_	_
8	permanent	_	JJ	_	_	9	NMOD	_	_
9	effects	_	NNS	_	_	7	VMOD	_	_
10	,	_	,	_	_	13	P	_	_
11	reversible	_	JJ	_	_	12	NMOD	_	_
12	mechanisms	_	NNS	_	_	13	VMOD	_	_
13	are	_	VBP	_	_	0	ROOT	_	_
14	gene	_	NN	_	_	15	NMOD	_	_
15	methylation	_	NN	_	_	13	VMOD	_	_
16	,	_	,	_	_	15	P	_	_
17	or	_	CC	_	_	15	COORD	_	_
18	expression	_	NN	_	_	17	CONJ	_	_
19	and	_	CC	_	_	18	COORD	_	_
20	activation	_	NN	_	_	19	CONJ	_	_
21	of	_	IN	_	_	18	NMOD	_	_
22	transcription	_	NN	_	_	23	NMOD	_	_
23	factors	_	NNS	_	_	21	PMOD	_	_
24	,	_	,	_	_	13	P	_	_
25	respectively	_	RB	_	_	13	VMOD	_	_
26	.	_	.	_	_	13	P	_	_
		
1	We	_	PRP	_	_	2	VMOD	_	_
2	studied	_	VBD	_	_	0	ROOT	_	_
3	a	_	DT	_	_	5	NMOD	_	_
4	putative	_	JJ	_	_	5	NMOD	_	_
5	cause	_	NN	_	_	2	VMOD	_	_
6	for	_	IN	_	_	5	NMOD	_	_
7	absent	_	JJ	_	_	9	NMOD	_	_
8	IRF-4	_	NN	_	_	9	NMOD	_	_
9	expression	_	NN	_	_	6	PMOD	_	_
10	in	_	IN	_	_	9	NMOD	_	_
11	leukemia	_	NN	_	_	12	NMOD	_	_
12	cells	_	NNS	_	_	10	PMOD	_	_
13	and	_	CC	_	_	2	COORD	_	_
14	first	_	RB	_	_	15	VMOD	_	_
15	focused	_	VBD	_	_	13	CONJ	_	_
16	on	_	IN	_	_	15	VMOD	_	_
17	genetic	_	JJ	_	_	18	NMOD	_	_
18	aberrations	_	NNS	_	_	16	PMOD	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	promoter	_	NN	_	_	19	PMOD	_	_
22	.	_	.	_	_	2	P	_	_
		
1	We	_	PRP	_	_	2	VMOD	_	_
2	observed	_	VBD	_	_	0	ROOT	_	_
3	no	_	DT	_	_	5	NMOD	_	_
4	genetic	_	JJ	_	_	5	NMOD	_	_
5	alterations	_	NNS	_	_	2	VMOD	_	_
6	in	_	IN	_	_	5	NMOD	_	_
7	the	_	DT	_	_	9	NMOD	_	_
8	IRF-4	_	NN	_	_	9	NMOD	_	_
9	promoter	_	NN	_	_	6	PMOD	_	_
10	,	_	,	_	_	5	P	_	_
11	which	_	WDT	_	_	12	VMOD	_	_
12	can	_	MD	_	_	5	NMOD	_	_
13	account	_	VB	_	_	12	VC	_	_
14	for	_	IN	_	_	13	VMOD	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	lack	_	NN	_	_	14	PMOD	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	IRF-4	_	NN	_	_	19	NMOD	_	_
19	expression	_	NN	_	_	17	PMOD	_	_
20	:	_	:	_	_	2	P	_	_
21	The	_	DT	_	_	25	NMOD	_	_
22	detected	_	VBN	_	_	25	NMOD	_	_
23	base	_	NN	_	_	25	NMOD	_	_
24	pair	_	NN	_	_	25	NMOD	_	_
25	changes	_	NNS	_	_	55	VMOD	_	_
26	at	_	IN	_	_	25	NMOD	_	_
27	position	_	NN	_	_	26	PMOD	_	_
28	-1081	_	CD	_	_	27	NMOD	_	_
29	(	_	(	_	_	33	P	_	_
30	T	_	NN	_	_	33	NMOD	_	_
31	to	_	TO	_	_	33	NMOD	_	_
32	C	_	NN	_	_	33	NMOD	_	_
33	substitution	_	NN	_	_	27	PRN	_	_
34	)	_	)	_	_	33	P	_	_
35	,	_	,	_	_	26	P	_	_
36	at	_	IN	_	_	26	COORD	_	_
37	position	_	NN	_	_	36	PMOD	_	_
38	-1068	_	CD	_	_	37	NMOD	_	_
39	(	_	(	_	_	43	P	_	_
40	A	_	NN	_	_	43	NMOD	_	_
41	to	_	TO	_	_	43	NMOD	_	_
42	C	_	NN	_	_	43	NMOD	_	_
43	substitution	_	NN	_	_	37	PRN	_	_
44	)	_	)	_	_	43	P	_	_
45	and	_	CC	_	_	36	COORD	_	_
46	at	_	IN	_	_	45	CONJ	_	_
47	position	_	NN	_	_	46	PMOD	_	_
48	-116	_	CD	_	_	47	NMOD	_	_
49	(	_	(	_	_	53	P	_	_
50	A	_	NN	_	_	53	NMOD	_	_
51	to	_	TO	_	_	53	NMOD	_	_
52	C	_	NN	_	_	53	NMOD	_	_
53	substitution	_	NN	_	_	47	PRN	_	_
54	)	_	)	_	_	53	P	_	_
55	are	_	VBP	_	_	2	COORD	_	_
56	unlikely	_	JJ	_	_	57	AMOD	_	_
57	responsible	_	JJ	_	_	55	VMOD	_	_
58	for	_	IN	_	_	57	AMOD	_	_
59	absent	_	JJ	_	_	60	NMOD	_	_
60	IRF-4-expression	_	NN	_	_	58	PMOD	_	_
61	since	_	IN	_	_	60	NMOD	_	_
62	the	_	DT	_	_	65	NMOD	_	_
63	first	_	JJ	_	_	65	NMOD	_	_
64	two	_	CD	_	_	65	NMOD	_	_
65	mutations	_	NNS	_	_	66	VMOD	_	_
66	were	_	VBD	_	_	61	SUB	_	_
67	found	_	VBN	_	_	66	VC	_	_
68	both	_	CC	_	_	69	DEP	_	_
69	in	_	IN	_	_	67	VMOD	_	_
70	IRF-4-positive	_	JJ	_	_	73	NMOD	_	_
71	and	_	CC	_	_	70	COORD	_	_
72	-negative	_	JJ	_	_	71	CONJ	_	_
73	cells	_	NNS	_	_	69	PMOD	_	_
74	whereas	_	IN	_	_	67	VMOD	_	_
75	the	_	DT	_	_	77	NMOD	_	_
76	latter	_	JJ	_	_	77	NMOD	_	_
77	change	_	NN	_	_	78	VMOD	_	_
78	was	_	VBD	_	_	74	PMOD	_	_
79	not	_	RB	_	_	78	VMOD	_	_
80	detected	_	VBN	_	_	78	VC	_	_
81	consistently	_	RB	_	_	80	VMOD	_	_
82	in	_	IN	_	_	80	VMOD	_	_
83	all	_	DT	_	_	87	NMOD	_	_
84	IRF-4-negative	_	JJ	_	_	87	NMOD	_	_
85	or	_	CC	_	_	84	COORD	_	_
86	-positive	_	JJ	_	_	85	CONJ	_	_
87	cells	_	NNS	_	_	82	PMOD	_	_
88	and	_	CC	_	_	78	COORD	_	_
89	may	_	MD	_	_	88	CONJ	_	_
90	thus	_	RB	_	_	89	VMOD	_	_
91	be	_	VB	_	_	89	VC	_	_
92	a	_	DT	_	_	93	NMOD	_	_
93	polymorphism	_	NN	_	_	91	VMOD	_	_
94	.	_	.	_	_	2	P	_	_
		
1	All	_	DT	_	_	3	NMOD	_	_
2	three	_	CD	_	_	3	NMOD	_	_
3	substitutions	_	NNS	_	_	4	VMOD	_	_
4	did	_	VBD	_	_	0	ROOT	_	_
5	not	_	RB	_	_	4	VMOD	_	_
6	change	_	VB	_	_	4	VC	_	_
7	any	_	DT	_	_	13	NMOD	_	_
8	known	_	JJ	_	_	13	NMOD	_	_
9	putative	_	JJ	_	_	13	NMOD	_	_
10	transcription	_	NN	_	_	13	NMOD	_	_
11	factor	_	NN	_	_	13	NMOD	_	_
12	binding	_	NN	_	_	13	NMOD	_	_
13	sites	_	NNS	_	_	6	VMOD	_	_
14	(	_	(	_	_	15	P	_	_
15	30,31	_	CD	_	_	6	PRN	_	_
16	)	_	)	_	_	15	P	_	_
17	and	_	CC	_	_	4	COORD	_	_
18	also	_	RB	_	_	4	VMOD	_	_
19	do	_	VBP	_	_	17	CONJ	_	_
20	not	_	RB	_	_	19	VMOD	_	_
21	affect	_	VB	_	_	19	VC	_	_
22	any	_	DT	_	_	24	NMOD	_	_
23	restriction	_	NN	_	_	24	NMOD	_	_
24	sites	_	NNS	_	_	21	VMOD	_	_
25	or	_	CC	_	_	24	COORD	_	_
26	primer	_	NN	_	_	28	NMOD	_	_
27	binding	_	NN	_	_	28	NMOD	_	_
28	sites	_	NNS	_	_	25	CONJ	_	_
29	of	_	IN	_	_	24	NMOD	_	_
30	the	_	DT	_	_	32	NMOD	_	_
31	used	_	VBN	_	_	32	NMOD	_	_
32	assays	_	NNS	_	_	29	PMOD	_	_
33	.	_	.	_	_	4	P	_	_
		
1	However	_	RB	_	_	20	VMOD	_	_
2	,	_	,	_	_	20	P	_	_
3	permanent	_	JJ	_	_	5	NMOD	_	_
4	genetic	_	JJ	_	_	5	NMOD	_	_
5	variations	_	NNS	_	_	20	VMOD	_	_
6	in	_	IN	_	_	5	NMOD	_	_
7	the	_	DT	_	_	10	NMOD	_	_
8	IRF-4	_	NN	_	_	10	NMOD	_	_
9	coding	_	NN	_	_	10	NMOD	_	_
10	sequence	_	NN	_	_	6	PMOD	_	_
11	,	_	,	_	_	5	P	_	_
12	such	_	JJ	_	_	13	DEP	_	_
13	as	_	IN	_	_	5	NMOD	_	_
14	deletions	_	NNS	_	_	13	PMOD	_	_
15	or	_	CC	_	_	14	COORD	_	_
16	mutations	_	NNS	_	_	15	CONJ	_	_
17	resulting	_	VBG	_	_	14	APPO	_	_
18	in	_	IN	_	_	17	VMOD	_	_
19	stop-codons	_	NNS	_	_	18	PMOD	_	_
20	have	_	VBP	_	_	0	ROOT	_	_
21	not	_	RB	_	_	20	VMOD	_	_
22	been	_	VBN	_	_	20	VC	_	_
23	excluded	_	VBN	_	_	22	VC	_	_
24	by	_	IN	_	_	23	VMOD	_	_
25	sequence	_	NN	_	_	26	NMOD	_	_
26	analysis	_	NN	_	_	24	PMOD	_	_
27	.	_	.	_	_	20	P	_	_
		
1	Since	_	IN	_	_	30	VMOD	_	_
2	IRF-4	_	NN	_	_	3	NMOD	_	_
3	expression	_	NN	_	_	9	VMOD	_	_
4	in	_	IN	_	_	3	NMOD	_	_
5	cell	_	NN	_	_	6	NMOD	_	_
6	lines	_	NNS	_	_	4	PMOD	_	_
7	and	_	CC	_	_	6	COORD	_	_
8	CML	_	NN	_	_	7	CONJ	_	_
9	can	_	MD	_	_	1	SUB	_	_
10	be	_	VB	_	_	9	VC	_	_
11	induced	_	VBN	_	_	10	VC	_	_
12	by	_	IN	_	_	11	VMOD	_	_
13	demethylation	_	NN	_	_	12	PMOD	_	_
14	and	_	CC	_	_	13	COORD	_	_
15	successful	_	JJ	_	_	17	NMOD	_	_
16	IFN-alpha	_	NN	_	_	17	NMOD	_	_
17	therapy	_	NN	_	_	14	CONJ	_	_
18	(	_	(	_	_	19	P	_	_
19	3	_	CD	_	_	17	PRN	_	_
20	)	_	)	_	_	19	P	_	_
21	,	_	,	_	_	11	P	_	_
22	respectively	_	RB	_	_	11	VMOD	_	_
23	,	_	,	_	_	30	P	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	existence	_	NN	_	_	30	VMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	such	_	JJ	_	_	29	NMOD	_	_
28	genetic	_	JJ	_	_	29	NMOD	_	_
29	aberrations	_	NNS	_	_	26	PMOD	_	_
30	seems	_	VBZ	_	_	0	ROOT	_	_
31	unlikely	_	JJ	_	_	30	VMOD	_	_
32	.	_	.	_	_	30	P	_	_
		
1	We	_	PRP	_	_	3	VMOD	_	_
2	then	_	RB	_	_	3	VMOD	_	_
3	investigated	_	VBD	_	_	0	ROOT	_	_
4	whether	_	IN	_	_	3	VMOD	_	_
5	the	_	DT	_	_	8	NMOD	_	_
6	previously	_	RB	_	_	7	AMOD	_	_
7	described	_	VBN	_	_	8	NMOD	_	_
8	down-regulation	_	NN	_	_	16	VMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	IRF-4	_	NN	_	_	11	NMOD	_	_
11	expression	_	NN	_	_	9	PMOD	_	_
12	in	_	IN	_	_	8	NMOD	_	_
13	human	_	JJ	_	_	15	NMOD	_	_
14	myeloid	_	JJ	_	_	15	NMOD	_	_
15	leukemias	_	NNS	_	_	12	PMOD	_	_
16	was	_	VBD	_	_	4	SUB	_	_
17	due	_	JJ	_	_	16	VMOD	_	_
18	to	_	TO	_	_	17	AMOD	_	_
19	a	_	DT	_	_	21	NMOD	_	_
20	differential	_	JJ	_	_	21	NMOD	_	_
21	hypermethylation	_	NN	_	_	18	PMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	promoter	_	NN	_	_	22	PMOD	_	_
25	,	_	,	_	_	16	P	_	_
26	since	_	IN	_	_	16	VMOD	_	_
27	the	_	DT	_	_	29	NMOD	_	_
28	presented	_	VBN	_	_	29	NMOD	_	_
29	re-expression	_	NN	_	_	33	VMOD	_	_
30	due	_	IN	_	_	29	NMOD	_	_
31	to	_	TO	_	_	30	DEP	_	_
32	AzadC-treatment	_	NN	_	_	30	PMOD	_	_
33	might	_	MD	_	_	26	SUB	_	_
34	also	_	RB	_	_	33	VMOD	_	_
35	be	_	VB	_	_	33	VC	_	_
36	a	_	DT	_	_	37	NMOD	_	_
37	result	_	NN	_	_	35	VMOD	_	_
38	of	_	IN	_	_	37	NMOD	_	_
39	activation	_	NN	_	_	38	PMOD	_	_
40	of	_	IN	_	_	39	NMOD	_	_
41	positive	_	JJ	_	_	43	NMOD	_	_
42	transcriptional	_	JJ	_	_	43	NMOD	_	_
43	regulators	_	NNS	_	_	40	PMOD	_	_
44	of	_	IN	_	_	43	NMOD	_	_
45	IRF-4	_	NN	_	_	44	PMOD	_	_
46	.	_	.	_	_	3	P	_	_
		
1	Methylation	_	NN	_	_	5	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	CpG	_	NN	_	_	4	NMOD	_	_
4	sites	_	NNS	_	_	2	PMOD	_	_
5	is	_	VBZ	_	_	0	ROOT	_	_
6	a	_	DT	_	_	8	NMOD	_	_
7	common	_	JJ	_	_	8	NMOD	_	_
8	mechanism	_	NN	_	_	5	VMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	silencing	_	JJ	_	_	11	NMOD	_	_
11	genes	_	NNS	_	_	9	PMOD	_	_
12	in	_	IN	_	_	11	NMOD	_	_
13	leukemia	_	NN	_	_	12	PMOD	_	_
14	and	_	CC	_	_	5	COORD	_	_
15	has	_	VBZ	_	_	14	CONJ	_	_
16	also	_	RB	_	_	15	VMOD	_	_
17	been	_	VBN	_	_	15	VC	_	_
18	shown	_	VBN	_	_	17	VC	_	_
19	for	_	IN	_	_	18	VMOD	_	_
20	another	_	DT	_	_	21	NMOD	_	_
21	IRF	_	NN	_	_	19	PMOD	_	_
22	,	_	,	_	_	21	P	_	_
23	IRF-7	_	NN	_	_	21	APPO	_	_
24	(	_	(	_	_	23	P	_	_
25	35	_	CD	_	_	23	NMOD	_	_
26	)	_	)	_	_	23	P	_	_
27	and	_	CC	_	_	19	COORD	_	_
28	for	_	IN	_	_	27	CONJ	_	_
29	PU.1	_	NN	_	_	28	PMOD	_	_
30	(	_	(	_	_	29	P	_	_
31	36	_	CD	_	_	29	NMOD	_	_
32	)	_	)	_	_	29	P	_	_
33	,	_	,	_	_	29	P	_	_
34	an	_	DT	_	_	36	NMOD	_	_
35	interacting	_	VBG	_	_	36	NMOD	_	_
36	partner	_	NN	_	_	29	APPO	_	_
37	of	_	IN	_	_	36	NMOD	_	_
38	IRF-4	_	NN	_	_	37	PMOD	_	_
39	.	_	.	_	_	5	P	_	_
		
1	To	_	TO	_	_	18	VC	_	_
2	elucidate	_	VB	_	_	1	IM	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	relevance	_	NN	_	_	2	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	this	_	DT	_	_	7	NMOD	_	_
7	mechanism	_	NN	_	_	5	PMOD	_	_
8	for	_	IN	_	_	4	NMOD	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	regulation	_	NN	_	_	8	PMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	IRF-4	_	NN	_	_	13	NMOD	_	_
13	expression	_	NN	_	_	11	PMOD	_	_
14	,	_	,	_	_	18	P	_	_
15	various	_	JJ	_	_	17	NMOD	_	_
16	leukemic	_	JJ	_	_	17	NMOD	_	_
17	cells	_	NNS	_	_	18	VMOD	_	_
18	were	_	VBD	_	_	0	ROOT	_	_
19	treated	_	VBN	_	_	18	VC	_	_
20	with	_	IN	_	_	19	VMOD	_	_
21	demethylating	_	JJ	_	_	22	NMOD	_	_
22	agents	_	NNS	_	_	20	PMOD	_	_
23	and	_	CC	_	_	18	COORD	_	_
24	promoters	_	NNS	_	_	25	VMOD	_	_
25	were	_	VBD	_	_	23	CONJ	_	_
26	sequenced	_	VBN	_	_	25	VC	_	_
27	after	_	IN	_	_	26	VMOD	_	_
28	bisulfite	_	NN	_	_	29	NMOD	_	_
29	treatment	_	NN	_	_	27	PMOD	_	_
30	.	_	.	_	_	18	P	_	_
		
1	We	_	PRP	_	_	2	VMOD	_	_
2	found	_	VBD	_	_	0	ROOT	_	_
3	that	_	IN	_	_	2	VMOD	_	_
4	IRF-4	_	NN	_	_	5	NMOD	_	_
5	expression	_	NN	_	_	6	VMOD	_	_
6	could	_	MD	_	_	3	SUB	_	_
7	indeed	_	RB	_	_	6	VMOD	_	_
8	be	_	VB	_	_	6	VC	_	_
9	connected	_	VBN	_	_	8	VC	_	_
10	to	_	TO	_	_	9	VMOD	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	methylation	_	NN	_	_	13	NMOD	_	_
13	status	_	NN	_	_	10	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	distinct	_	JJ	_	_	17	NMOD	_	_
16	CpG	_	NN	_	_	17	NMOD	_	_
17	motifs	_	NNS	_	_	14	PMOD	_	_
18	in	_	IN	_	_	13	NMOD	_	_
19	the	_	DT	_	_	21	NMOD	_	_
20	IRF-4	_	NN	_	_	21	NMOD	_	_
21	promoter	_	NN	_	_	18	PMOD	_	_
22	.	_	.	_	_	2	P	_	_
		
1	In	_	IN	_	_	8	VMOD	_	_
2	Figure	_	NN	_	_	1	PMOD	_	_
3	4A	_	CD	_	_	2	NMOD	_	_
4	,	_	,	_	_	8	P	_	_
5	those	_	DT	_	_	7	NMOD	_	_
6	CpG	_	NN	_	_	7	NMOD	_	_
7	sites	_	NNS	_	_	8	VMOD	_	_
8	are	_	VBP	_	_	0	ROOT	_	_
9	shown	_	VBN	_	_	8	VMOD	_	_
10	(	_	(	_	_	12	P	_	_
11	bottom	_	NN	_	_	12	NMOD	_	_
12	line	_	NN	_	_	9	PRN	_	_
13	)	_	)	_	_	12	P	_	_
14	,	_	,	_	_	9	P	_	_
15	whose	_	WP$	_	_	16	NMOD	_	_
16	hypermethylation	_	NN	_	_	17	VMOD	_	_
17	may	_	MD	_	_	9	NMOD	_	_
18	account	_	VB	_	_	17	VC	_	_
19	for	_	IN	_	_	18	VMOD	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	absence	_	NN	_	_	19	PMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	IRF-4	_	NN	_	_	24	NMOD	_	_
24	expression	_	NN	_	_	22	PMOD	_	_
25	in	_	IN	_	_	24	NMOD	_	_
26	the	_	DT	_	_	28	NMOD	_	_
27	respective	_	JJ	_	_	28	NMOD	_	_
28	cells	_	NNS	_	_	25	PMOD	_	_
29	.	_	.	_	_	8	P	_	_
		
1	One	_	CD	_	_	7	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	them	_	PRP	_	_	2	PMOD	_	_
4	(	_	(	_	_	5	P	_	_
5	#54	_	NN	_	_	1	PRN	_	_
6	)	_	)	_	_	5	P	_	_
7	is	_	VBZ	_	_	0	ROOT	_	_
8	adjacent	_	JJ	_	_	7	VMOD	_	_
9	to	_	TO	_	_	8	AMOD	_	_
10	an	_	DT	_	_	13	NMOD	_	_
11	identified	_	VBN	_	_	13	NMOD	_	_
12	regulatory	_	JJ	_	_	13	NMOD	_	_
13	element	_	NN	_	_	9	PMOD	_	_
14	(	_	(	_	_	15	P	_	_
15	NFkappaB-site	_	NN	_	_	13	PRN	_	_
16	)	_	)	_	_	15	P	_	_
17	,	_	,	_	_	7	P	_	_
18	indicating	_	VBG	_	_	7	VC	_	_
19	a	_	DT	_	_	21	NMOD	_	_
20	possible	_	JJ	_	_	21	NMOD	_	_
21	involvement	_	NN	_	_	18	VMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	this	_	DT	_	_	24	NMOD	_	_
24	site	_	NN	_	_	22	PMOD	_	_
25	.	_	.	_	_	7	P	_	_
		
1	At	_	IN	_	_	16	VMOD	_	_
2	two	_	CD	_	_	5	NMOD	_	_
3	further	_	JJ	_	_	5	NMOD	_	_
4	CpG	_	NN	_	_	5	NMOD	_	_
5	sites	_	NNS	_	_	1	PMOD	_	_
6	(	_	(	_	_	7	P	_	_
7	#48	_	CD	_	_	5	PRN	_	_
8	,	_	,	_	_	7	P	_	_
9	45	_	CD	_	_	7	APPO	_	_
10	)	_	)	_	_	7	P	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	methylation	_	NN	_	_	13	NMOD	_	_
13	status	_	NN	_	_	16	VMOD	_	_
14	in	_	IN	_	_	13	NMOD	_	_
15	IRF-4-positive	_	NN	_	_	14	PMOD	_	_
16	was	_	VBD	_	_	0	ROOT	_	_
17	lower	_	JJR	_	_	16	VMOD	_	_
18	than	_	IN	_	_	17	AMOD	_	_
19	that	_	DT	_	_	18	PMOD	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	IRF-4-negative	_	JJ	_	_	22	NMOD	_	_
22	cells	_	NNS	_	_	20	PMOD	_	_
23	.	_	.	_	_	16	P	_	_
		
1	These	_	DT	_	_	3	NMOD	_	_
2	CpG	_	NN	_	_	3	NMOD	_	_
3	sites	_	NNS	_	_	4	VMOD	_	_
4	are	_	VBP	_	_	0	ROOT	_	_
5	located	_	JJ	_	_	4	VMOD	_	_
6	in	_	IN	_	_	5	AMOD	_	_
7	an	_	DT	_	_	8	NMOD	_	_
8	NFkappaB	_	NN	_	_	6	PMOD	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	an	_	DT	_	_	12	NMOD	_	_
11	SP1	_	NN	_	_	12	NMOD	_	_
12	element	_	NN	_	_	9	CONJ	_	_
13	(	_	(	_	_	14	P	_	_
14	31	_	CD	_	_	12	PRN	_	_
15	)	_	)	_	_	14	P	_	_
16	and	_	CC	_	_	4	COORD	_	_
17	thus	_	RB	_	_	18	VMOD	_	_
18	may	_	MD	_	_	16	CONJ	_	_
19	also	_	RB	_	_	18	VMOD	_	_
20	play	_	VB	_	_	18	VC	_	_
21	a	_	DT	_	_	22	NMOD	_	_
22	role	_	NN	_	_	20	VMOD	_	_
23	in	_	IN	_	_	20	VMOD	_	_
24	regulation	_	NN	_	_	23	PMOD	_	_
25	of	_	IN	_	_	24	NMOD	_	_
26	IRF-4	_	NN	_	_	27	NMOD	_	_
27	expression	_	NN	_	_	25	PMOD	_	_
28	.	_	.	_	_	4	P	_	_
		
1	It	_	PRP	_	_	2	VMOD	_	_
2	has	_	VBZ	_	_	0	ROOT	_	_
3	been	_	VBN	_	_	2	VC	_	_
4	shown	_	VBN	_	_	3	VC	_	_
5	that	_	IN	_	_	4	VMOD	_	_
6	NFkappaB	_	NN	_	_	7	NMOD	_	_
7	elements	_	NNS	_	_	8	VMOD	_	_
8	play	_	VBP	_	_	5	SUB	_	_
9	an	_	DT	_	_	11	NMOD	_	_
10	important	_	JJ	_	_	11	NMOD	_	_
11	role	_	NN	_	_	8	VMOD	_	_
12	in	_	IN	_	_	8	VMOD	_	_
13	IRF-4	_	NN	_	_	14	NMOD	_	_
14	induction	_	NN	_	_	12	PMOD	_	_
15	as	_	IN	_	_	8	VMOD	_	_
16	IRF-4	_	NN	_	_	17	NMOD	_	_
17	expression	_	NN	_	_	18	VMOD	_	_
18	depends	_	VBZ	_	_	15	SUB	_	_
19	on	_	IN	_	_	18	VMOD	_	_
20	binding	_	NN	_	_	19	PMOD	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	the	_	DT	_	_	24	NMOD	_	_
23	transactivator	_	NN	_	_	24	NMOD	_	_
24	c-Rel	_	NN	_	_	21	PMOD	_	_
25	to	_	TO	_	_	20	NMOD	_	_
26	these	_	DT	_	_	27	NMOD	_	_
27	elements	_	NNS	_	_	25	PMOD	_	_
28	in	_	IN	_	_	27	NMOD	_	_
29	the	_	DT	_	_	31	NMOD	_	_
30	IRF-4	_	NN	_	_	31	NMOD	_	_
31	promoter	_	NN	_	_	28	PMOD	_	_
32	(	_	(	_	_	33	P	_	_
33	31,37	_	NN	_	_	31	PRN	_	_
34	)	_	)	_	_	33	P	_	_
35	.	_	.	_	_	2	P	_	_
		
1	Furthermore	_	RB	_	_	12	VMOD	_	_
2	,	_	,	_	_	12	P	_	_
3	methylation	_	NN	_	_	12	VMOD	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	the	_	DT	_	_	7	NMOD	_	_
6	central	_	JJ	_	_	7	NMOD	_	_
7	CpG	_	NN	_	_	4	PMOD	_	_
8	in	_	IN	_	_	3	NMOD	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	NFkappaB	_	NN	_	_	11	NMOD	_	_
11	element	_	NN	_	_	8	PMOD	_	_
12	inhibits	_	VBZ	_	_	0	ROOT	_	_
13	binding	_	NN	_	_	12	VMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	the	_	DT	_	_	18	NMOD	_	_
16	NFkappaB	_	NN	_	_	18	NMOD	_	_
17	protein	_	NN	_	_	18	NMOD	_	_
18	complexes	_	NNS	_	_	14	PMOD	_	_
19	(	_	(	_	_	20	P	_	_
20	38	_	CD	_	_	18	PRN	_	_
21	)	_	)	_	_	20	P	_	_
22	,	_	,	_	_	12	P	_	_
23	promoting	_	VBG	_	_	12	VMOD	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	significance	_	NN	_	_	23	VMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	the	_	DT	_	_	30	NMOD	_	_
28	observed	_	VBN	_	_	30	NMOD	_	_
29	methylation	_	NN	_	_	30	NMOD	_	_
30	differences	_	NNS	_	_	26	PMOD	_	_
31	in	_	IN	_	_	30	NMOD	_	_
32	IRF-4-positive	_	JJ	_	_	35	NMOD	_	_
33	and	_	CC	_	_	32	COORD	_	_
34	-negative	_	JJ	_	_	33	CONJ	_	_
35	cells	_	NNS	_	_	31	PMOD	_	_
36	.	_	.	_	_	12	P	_	_
		
1	Via	_	IN	_	_	10	VMOD	_	_
2	in	_	FW	_	_	3	AMOD	_	_
3	vitro	_	FW	_	_	8	NMOD	_	_
4	methylation	_	NN	_	_	8	NMOD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	reporter	_	NN	_	_	5	CONJ	_	_
7	gene	_	NN	_	_	8	NMOD	_	_
8	assays	_	NNS	_	_	1	PMOD	_	_
9	we	_	PRP	_	_	10	VMOD	_	_
10	could	_	MD	_	_	0	ROOT	_	_
11	clearly	_	RB	_	_	10	VMOD	_	_
12	appoint	_	NN	_	_	10	VC	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	silencing	_	NN	_	_	12	VMOD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	the	_	DT	_	_	18	NMOD	_	_
17	IRF-4	_	NN	_	_	18	NMOD	_	_
18	promoter	_	NN	_	_	15	PMOD	_	_
19	to	_	TO	_	_	12	VMOD	_	_
20	a	_	DT	_	_	22	NMOD	_	_
21	methylation	_	NN	_	_	22	NMOD	_	_
22	effect	_	NN	_	_	19	PMOD	_	_
23	,	_	,	_	_	22	P	_	_
24	which	_	WDT	_	_	25	VMOD	_	_
25	may	_	MD	_	_	22	NMOD	_	_
26	thus	_	RB	_	_	25	VMOD	_	_
27	be	_	VB	_	_	25	VC	_	_
28	the	_	DT	_	_	29	NMOD	_	_
29	mechanism	_	NN	_	_	27	VMOD	_	_
30	of	_	IN	_	_	29	NMOD	_	_
31	IRF-4	_	NN	_	_	32	NMOD	_	_
32	deregulation	_	NN	_	_	30	PMOD	_	_
33	in	_	FW	_	_	27	VMOD	_	_
34	vivo	_	FW	_	_	33	AMOD	_	_
35	.	_	.	_	_	10	P	_	_
		
1	One	_	CD	_	_	3	NMOD	_	_
2	possible	_	JJ	_	_	3	NMOD	_	_
3	cause	_	NN	_	_	10	VMOD	_	_
4	for	_	IN	_	_	3	NMOD	_	_
5	the	_	DT	_	_	7	NMOD	_	_
6	aberrant	_	JJ	_	_	7	NMOD	_	_
7	methylation	_	NN	_	_	4	PMOD	_	_
8	in	_	IN	_	_	7	NMOD	_	_
9	tumorigenesis	_	NN	_	_	8	PMOD	_	_
10	is	_	VBZ	_	_	0	ROOT	_	_
11	an	_	DT	_	_	13	NMOD	_	_
12	increased	_	VBN	_	_	13	NMOD	_	_
13	level	_	NN	_	_	10	VMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	DNMTs	_	NNS	_	_	14	PMOD	_	_
16	during	_	IN	_	_	10	VMOD	_	_
17	the	_	DT	_	_	19	NMOD	_	_
18	pathogenetic	_	JJ	_	_	19	NMOD	_	_
19	process	_	NN	_	_	16	PMOD	_	_
20	.	_	.	_	_	10	P	_	_
		
1	In	_	IN	_	_	17	VMOD	_	_
2	colon	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	2	P	_	_
4	lung	_	NN	_	_	2	COORD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	hematologic	_	JJ	_	_	7	NMOD	_	_
7	malignancies	_	NNS	_	_	5	CONJ	_	_
8	,	_	,	_	_	17	P	_	_
9	overexpression	_	NN	_	_	17	VMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	DNMT1	_	NN	_	_	10	PMOD	_	_
12	,	_	,	_	_	11	P	_	_
13	a	_	DT	_	_	15	NMOD	_	_
14	maintenance	_	NN	_	_	15	NMOD	_	_
15	DNMT	_	NN	_	_	11	APPO	_	_
16	,	_	,	_	_	11	P	_	_
17	has	_	VBZ	_	_	0	ROOT	_	_
18	been	_	VBN	_	_	17	VC	_	_
19	detected	_	VBN	_	_	18	VC	_	_
20	(	_	(	_	_	21	P	_	_
21	39-41	_	NN	_	_	19	PRN	_	_
22	)	_	)	_	_	21	P	_	_
23	.	_	.	_	_	17	P	_	_
		
1	Furthermore	_	RB	_	_	4	VMOD	_	_
2	,	_	,	_	_	4	P	_	_
3	it	_	PRP	_	_	4	VMOD	_	_
4	has	_	VBZ	_	_	0	ROOT	_	_
5	been	_	VBN	_	_	4	VC	_	_
6	shown	_	VBN	_	_	5	VC	_	_
7	that	_	IN	_	_	6	VMOD	_	_
8	CML	_	NN	_	_	9	NMOD	_	_
9	cells	_	NNS	_	_	14	VMOD	_	_
10	in	_	IN	_	_	9	NMOD	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	acute	_	JJ	_	_	13	NMOD	_	_
13	phase	_	NN	_	_	10	PMOD	_	_
14	exhibited	_	VBD	_	_	7	SUB	_	_
15	elevated	_	JJ	_	_	16	NMOD	_	_
16	levels	_	NNS	_	_	14	VMOD	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	the	_	DT	_	_	21	NMOD	_	_
19	three	_	CD	_	_	21	NMOD	_	_
20	known	_	JJ	_	_	21	NMOD	_	_
21	DNMTs	_	NNS	_	_	17	PMOD	_	_
22	,	_	,	_	_	14	P	_	_
23	while	_	IN	_	_	14	VMOD	_	_
24	CML	_	NN	_	_	25	NMOD	_	_
25	cells	_	NNS	_	_	29	VMOD	_	_
26	in	_	IN	_	_	25	NMOD	_	_
27	chronic	_	JJ	_	_	28	NMOD	_	_
28	phase	_	NN	_	_	26	PMOD	_	_
29	expressed	_	VBD	_	_	23	SUB	_	_
30	normal	_	JJ	_	_	31	NMOD	_	_
31	levels	_	NNS	_	_	29	VMOD	_	_
32	of	_	IN	_	_	31	NMOD	_	_
33	DNMTs	_	NNS	_	_	32	PMOD	_	_
34	if	_	IN	_	_	29	VMOD	_	_
35	compared	_	VBN	_	_	34	SUB	_	_
36	with	_	IN	_	_	35	VMOD	_	_
37	normal	_	JJ	_	_	40	NMOD	_	_
38	bone	_	NN	_	_	40	NMOD	_	_
39	marrow	_	NN	_	_	40	NMOD	_	_
40	cells	_	NNS	_	_	36	PMOD	_	_
41	(	_	(	_	_	42	P	_	_
42	25	_	CD	_	_	40	PRN	_	_
43	)	_	)	_	_	42	P	_	_
44	.	_	.	_	_	4	P	_	_
		
1	Interestingly	_	RB	_	_	14	VMOD	_	_
2	,	_	,	_	_	14	P	_	_
3	a	_	DT	_	_	5	NMOD	_	_
4	positive	_	JJ	_	_	5	NMOD	_	_
5	correlation	_	NN	_	_	14	VMOD	_	_
6	between	_	IN	_	_	5	NMOD	_	_
7	DNMT1	_	NN	_	_	9	NMOD	_	_
8	expression	_	NN	_	_	9	NMOD	_	_
9	levels	_	NNS	_	_	6	PMOD	_	_
10	and	_	CC	_	_	9	COORD	_	_
11	hypermethylation	_	NN	_	_	10	CONJ	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	p15INK4b	_	NN	_	_	12	PMOD	_	_
14	has	_	VBZ	_	_	0	ROOT	_	_
15	been	_	VBN	_	_	14	VC	_	_
16	detected	_	VBN	_	_	15	VC	_	_
17	in	_	IN	_	_	16	VMOD	_	_
18	AML	_	NN	_	_	17	PMOD	_	_
19	(	_	(	_	_	18	P	_	_
20	25	_	CD	_	_	18	NMOD	_	_
21	)	_	)	_	_	18	P	_	_
22	.	_	.	_	_	14	P	_	_
		
1	In	_	IN	_	_	6	VMOD	_	_
2	this	_	DT	_	_	3	NMOD	_	_
3	work	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	6	P	_	_
5	we	_	PRP	_	_	6	VMOD	_	_
6	did	_	VBD	_	_	0	ROOT	_	_
7	not	_	RB	_	_	6	VMOD	_	_
8	detect	_	VB	_	_	6	VC	_	_
9	significant	_	JJ	_	_	12	NMOD	_	_
10	mRNA	_	NN	_	_	12	NMOD	_	_
11	expression	_	NN	_	_	12	NMOD	_	_
12	differences	_	NNS	_	_	8	VMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	selected	_	VBN	_	_	15	NMOD	_	_
15	DNMT	_	NN	_	_	13	PMOD	_	_
16	or	_	CC	_	_	15	COORD	_	_
17	MBP	_	NN	_	_	16	CONJ	_	_
18	,	_	,	_	_	6	P	_	_
19	making	_	VBG	_	_	6	VMOD	_	_
20	it	_	PRP	_	_	19	VMOD	_	_
21	an	_	DT	_	_	23	NMOD	_	_
22	unlikely	_	JJ	_	_	23	NMOD	_	_
23	cause	_	NN	_	_	20	APPO	_	_
24	for	_	IN	_	_	23	NMOD	_	_
25	the	_	DT	_	_	32	NMOD	_	_
26	observed	_	VBN	_	_	32	NMOD	_	_
27	methylation	_	NN	_	_	32	NMOD	_	_
28	and	_	CC	_	_	27	COORD	_	_
29	thus	_	RB	_	_	31	NMOD	_	_
30	IRF-4	_	NN	_	_	31	NMOD	_	_
31	expression	_	NN	_	_	28	CONJ	_	_
32	differences	_	NNS	_	_	24	PMOD	_	_
33	in	_	IN	_	_	32	NMOD	_	_
34	leukemia	_	NN	_	_	35	NMOD	_	_
35	cells	_	NNS	_	_	33	PMOD	_	_
36	.	_	.	_	_	6	P	_	_
		
1	The	_	DT	_	_	2	NMOD	_	_
2	finding	_	NN	_	_	11	VMOD	_	_
3	that	_	IN	_	_	2	NMOD	_	_
4	IRF-4	_	NN	_	_	5	NMOD	_	_
5	expression	_	NN	_	_	6	VMOD	_	_
6	is	_	VBZ	_	_	3	SUB	_	_
7	silenced	_	VBN	_	_	6	VC	_	_
8	by	_	IN	_	_	7	VMOD	_	_
9	promoter	_	NN	_	_	10	NMOD	_	_
10	hypermethylation	_	NN	_	_	8	PMOD	_	_
11	might	_	MD	_	_	0	ROOT	_	_
12	represent	_	VB	_	_	11	VC	_	_
13	a	_	DT	_	_	14	NMOD	_	_
14	mechanism	_	NN	_	_	12	VMOD	_	_
15	that	_	WDT	_	_	16	VMOD	_	_
16	accounts	_	VBZ	_	_	14	NMOD	_	_
17	for	_	IN	_	_	16	VMOD	_	_
18	the	_	DT	_	_	21	NMOD	_	_
19	previously	_	RB	_	_	20	AMOD	_	_
20	observed	_	VBN	_	_	21	NMOD	_	_
21	loss	_	NN	_	_	17	PMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	IRF-4	_	NN	_	_	24	NMOD	_	_
24	expression	_	NN	_	_	22	PMOD	_	_
25	in	_	IN	_	_	24	NMOD	_	_
26	CML	_	NN	_	_	25	PMOD	_	_
27	.	_	.	_	_	11	P	_	_
		
1	Indeed	_	RB	_	_	14	VMOD	_	_
2	,	_	,	_	_	14	P	_	_
3	several	_	JJ	_	_	5	NMOD	_	_
4	clinical	_	JJ	_	_	5	NMOD	_	_
5	trials	_	NNS	_	_	14	VMOD	_	_
6	with	_	IN	_	_	5	NMOD	_	_
7	leukemia	_	NN	_	_	8	NMOD	_	_
8	patients	_	NNS	_	_	6	PMOD	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	patients	_	NNS	_	_	9	CONJ	_	_
11	with	_	IN	_	_	10	NMOD	_	_
12	myelodysplastic	_	JJ	_	_	13	NMOD	_	_
13	syndromes	_	NNS	_	_	11	PMOD	_	_
14	demonstrated	_	VBD	_	_	0	ROOT	_	_
15	the	_	DT	_	_	18	NMOD	_	_
16	potential	_	JJ	_	_	18	NMOD	_	_
17	clinical	_	JJ	_	_	18	NMOD	_	_
18	benefit	_	NN	_	_	14	VMOD	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	a	_	DT	_	_	21	NMOD	_	_
21	treatment	_	NN	_	_	19	PMOD	_	_
22	with	_	IN	_	_	21	NMOD	_	_
23	demethylating	_	JJ	_	_	24	NMOD	_	_
24	agents	_	NNS	_	_	22	PMOD	_	_
25	(	_	(	_	_	26	P	_	_
26	42-45	_	NN	_	_	24	PRN	_	_
27	)	_	)	_	_	26	P	_	_
28	.	_	.	_	_	14	P	_	_
		
1	The	_	DT	_	_	2	NMOD	_	_
2	expression	_	NN	_	_	16	VMOD	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	another	_	DT	_	_	5	NMOD	_	_
5	IRF	_	NN	_	_	3	PMOD	_	_
6	,	_	,	_	_	2	P	_	_
7	IFN	_	NN	_	_	11	NMOD	_	_
8	consensus	_	NN	_	_	11	NMOD	_	_
9	sequence	_	NN	_	_	11	NMOD	_	_
10	binding	_	NN	_	_	11	NMOD	_	_
11	protein	_	NN	_	_	2	APPO	_	_
12	(	_	(	_	_	13	P	_	_
13	ICSBP/IRF-8	_	NN	_	_	11	PRN	_	_
14	)	_	)	_	_	13	P	_	_
15	,	_	,	_	_	2	P	_	_
16	is	_	VBZ	_	_	0	ROOT	_	_
17	impaired	_	VBN	_	_	16	VC	_	_
18	in	_	IN	_	_	17	VMOD	_	_
19	myeloid	_	JJ	_	_	20	NMOD	_	_
20	leukemias	_	NNS	_	_	18	PMOD	_	_
21	especially	_	RB	_	_	22	NMOD	_	_
22	CML	_	NN	_	_	20	APPO	_	_
23	(	_	(	_	_	24	P	_	_
24	27,46,47	_	NN	_	_	22	PRN	_	_
25	)	_	)	_	_	24	P	_	_
26	.	_	.	_	_	16	P	_	_
		
1	But	_	CC	_	_	2	DEP	_	_
2	in	_	IN	_	_	0	ROOT	_	_
3	contrast	_	NN	_	_	2	DEP	_	_
4	to	_	TO	_	_	2	DEP	_	_
5	IRF-4	_	NN	_	_	2	PMOD	_	_
6	,	_	,	_	_	2	P	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	loss	_	NN	_	_	12	VMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	this	_	DT	_	_	11	NMOD	_	_
11	IRF	_	NN	_	_	9	PMOD	_	_
12	could	_	MD	_	_	2	COORD	_	_
13	not	_	RB	_	_	12	VMOD	_	_
14	be	_	VB	_	_	12	VC	_	_
15	reverted	_	VBD	_	_	14	VC	_	_
16	in	_	IN	_	_	15	VMOD	_	_
17	ICSBP-negative	_	JJ	_	_	19	NMOD	_	_
18	cell	_	NN	_	_	19	NMOD	_	_
19	lines	_	NNS	_	_	16	PMOD	_	_
20	(	_	(	_	_	21	P	_	_
21	EM-2	_	NN	_	_	19	PRN	_	_
22	,	_	,	_	_	21	P	_	_
23	CML-T1	_	NN	_	_	21	COORD	_	_
24	,	_	,	_	_	23	P	_	_
25	K-562	_	NN	_	_	23	COORD	_	_
26	and	_	CC	_	_	25	COORD	_	_
27	LAMA-84	_	CD	_	_	26	CONJ	_	_
28	)	_	)	_	_	21	P	_	_
29	by	_	IN	_	_	15	VMOD	_	_
30	treatment	_	NN	_	_	29	PMOD	_	_
31	with	_	IN	_	_	30	NMOD	_	_
32	AzadC	_	NN	_	_	31	PMOD	_	_
33	(	_	(	_	_	34	P	_	_
34	Figure	_	NN	_	_	32	PRN	_	_
35	6	_	CD	_	_	34	NMOD	_	_
36	)	_	)	_	_	34	P	_	_
37	and	_	CC	_	_	12	COORD	_	_
38	AzadC	_	NN	_	_	39	VMOD	_	_
39	has	_	VBZ	_	_	37	CONJ	_	_
40	no	_	DT	_	_	41	NMOD	_	_
41	effect	_	NN	_	_	39	VMOD	_	_
42	on	_	IN	_	_	39	VMOD	_	_
43	ICSBP	_	NN	_	_	44	NMOD	_	_
44	levels	_	NNS	_	_	42	PMOD	_	_
45	in	_	IN	_	_	44	NMOD	_	_
46	ICSBP-positive	_	JJ	_	_	48	NMOD	_	_
47	U-937	_	NN	_	_	48	NMOD	_	_
48	cells	_	NNS	_	_	45	PMOD	_	_
49	(	_	(	_	_	50	P	_	_
50	Figure	_	NN	_	_	48	PRN	_	_
51	6	_	CD	_	_	50	NMOD	_	_
52	)	_	)	_	_	50	P	_	_
53	.	_	.	_	_	2	P	_	_
		
1	These	_	DT	_	_	2	NMOD	_	_
2	data	_	NNS	_	_	3	VMOD	_	_
3	suggest	_	VBP	_	_	0	ROOT	_	_
4	a	_	DT	_	_	7	NMOD	_	_
5	distinct	_	JJ	_	_	7	NMOD	_	_
6	regulatory	_	JJ	_	_	7	NMOD	_	_
7	mechanism	_	NN	_	_	3	VMOD	_	_
8	for	_	IN	_	_	7	NMOD	_	_
9	these	_	DT	_	_	11	NMOD	_	_
10	two	_	CD	_	_	11	NMOD	_	_
11	IRFs	_	NNS	_	_	8	PMOD	_	_
12	.	_	.	_	_	3	P	_	_
		
1	IRF-4	_	NN	_	_	17	VMOD	_	_
2	,	_	,	_	_	1	P	_	_
3	similar	_	JJ	_	_	1	APPO	_	_
4	to	_	TO	_	_	3	AMOD	_	_
5	many	_	JJ	_	_	10	NMOD	_	_
6	other	_	JJ	_	_	10	NMOD	_	_
7	classical	_	JJ	_	_	10	NMOD	_	_
8	tumor	_	NN	_	_	10	NMOD	_	_
9	suppressor	_	NN	_	_	10	NMOD	_	_
10	genes	_	NNS	_	_	4	PMOD	_	_
11	p15INK4b	_	NN	_	_	10	NMOD	_	_
12	,	_	,	_	_	11	P	_	_
13	p16INK4a	_	NN	_	_	11	COORD	_	_
14	or	_	CC	_	_	13	COORD	_	_
15	p53	_	NN	_	_	14	CONJ	_	_
16	,	_	,	_	_	1	P	_	_
17	may	_	MD	_	_	0	ROOT	_	_
18	thus	_	RB	_	_	17	VMOD	_	_
19	be	_	VB	_	_	17	VC	_	_
20	a	_	DT	_	_	21	NMOD	_	_
21	subject	_	NN	_	_	19	VMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	alterations	_	NNS	_	_	22	PMOD	_	_
24	in	_	IN	_	_	23	NMOD	_	_
25	the	_	DT	_	_	28	NMOD	_	_
26	promoter	_	NN	_	_	28	NMOD	_	_
27	methylation	_	NN	_	_	28	NMOD	_	_
28	status	_	NN	_	_	24	PMOD	_	_
29	leading	_	VBG	_	_	28	APPO	_	_
30	to	_	TO	_	_	29	VMOD	_	_
31	expression	_	NN	_	_	32	NMOD	_	_
32	changes	_	NNS	_	_	30	PMOD	_	_
33	,	_	,	_	_	32	P	_	_
34	which	_	WDT	_	_	35	VMOD	_	_
35	might	_	MD	_	_	32	NMOD	_	_
36	contribute	_	VB	_	_	35	VC	_	_
37	to	_	TO	_	_	36	VMOD	_	_
38	the	_	DT	_	_	39	NMOD	_	_
39	initiation	_	NN	_	_	37	PMOD	_	_
40	and/or	_	CC	_	_	39	COORD	_	_
41	progression	_	NN	_	_	40	CONJ	_	_
42	of	_	IN	_	_	39	NMOD	_	_
43	cancer	_	NN	_	_	42	PMOD	_	_
44	.	_	.	_	_	17	P	_	_
		
1	Still	_	RB	_	_	9	VMOD	_	_
2	,	_	,	_	_	9	P	_	_
3	the	_	DT	_	_	6	NMOD	_	_
4	obvious	_	JJ	_	_	6	NMOD	_	_
5	functional	_	JJ	_	_	6	NMOD	_	_
6	diversity	_	NN	_	_	9	VMOD	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	IRF-4	_	NN	_	_	7	PMOD	_	_
9	remains	_	VBZ	_	_	0	ROOT	_	_
10	remarkable	_	JJ	_	_	9	VMOD	_	_
11	and	_	CC	_	_	9	COORD	_	_
12	can	_	MD	_	_	11	CONJ	_	_
13	not	_	RB	_	_	12	VMOD	_	_
14	be	_	VB	_	_	12	VC	_	_
15	fully	_	RB	_	_	14	VMOD	_	_
16	explained	_	VBN	_	_	14	VC	_	_
17	by	_	IN	_	_	16	VMOD	_	_
18	the	_	DT	_	_	22	NMOD	_	_
19	IRF-4	_	NN	_	_	22	NMOD	_	_
20	promoter	_	NN	_	_	22	NMOD	_	_
21	methylation	_	NN	_	_	22	NMOD	_	_
22	status	_	NN	_	_	17	PMOD	_	_
23	.	_	.	_	_	9	P	_	_
		
1	For	_	IN	_	_	5	VMOD	_	_
2	example	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	5	P	_	_
4	IRF-4	_	NN	_	_	5	VMOD	_	_
5	is	_	VBZ	_	_	0	ROOT	_	_
6	primarily	_	RB	_	_	5	VMOD	_	_
7	known	_	VBN	_	_	5	VC	_	_
8	for	_	IN	_	_	7	VMOD	_	_
9	its	_	PRP$	_	_	11	NMOD	_	_
10	oncogenic	_	JJ	_	_	11	NMOD	_	_
11	features	_	NNS	_	_	8	PMOD	_	_
12	.	_	.	_	_	5	P	_	_
		
1	In	_	IN	_	_	12	VMOD	_	_
2	multiple	_	JJ	_	_	3	NMOD	_	_
3	myeloma	_	NN	_	_	1	PMOD	_	_
4	(	_	(	_	_	5	P	_	_
5	MM	_	NN	_	_	3	PRN	_	_
6	)	_	)	_	_	5	P	_	_
7	a	_	DT	_	_	8	NMOD	_	_
8	translocation	_	NN	_	_	12	VMOD	_	_
9	on	_	IN	_	_	8	NMOD	_	_
10	chromosome	_	NN	_	_	9	PMOD	_	_
11	14q	_	CD	_	_	10	NMOD	_	_
12	was	_	VBD	_	_	0	ROOT	_	_
13	reported	_	VBN	_	_	12	VC	_	_
14	to	_	TO	_	_	13	VMOD	_	_
15	lead	_	VB	_	_	14	IM	_	_
16	to	_	TO	_	_	15	VMOD	_	_
17	a	_	DT	_	_	19	NMOD	_	_
18	fusion	_	NN	_	_	19	NMOD	_	_
19	gene	_	NN	_	_	16	PMOD	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	immunoglobulin	_	NN	_	_	22	NMOD	_	_
22	heavy-chain	_	NN	_	_	20	PMOD	_	_
23	(	_	(	_	_	24	P	_	_
24	IgH	_	NN	_	_	22	PRN	_	_
25	)	_	)	_	_	24	P	_	_
26	and	_	CC	_	_	22	COORD	_	_
27	IRF-4	_	NN	_	_	26	CONJ	_	_
28	resulting	_	VBG	_	_	22	APPO	_	_
29	in	_	IN	_	_	28	VMOD	_	_
30	a	_	DT	_	_	32	NMOD	_	_
31	subsequent	_	JJ	_	_	32	NMOD	_	_
32	overexpression	_	NN	_	_	29	PMOD	_	_
33	of	_	IN	_	_	32	NMOD	_	_
34	IRF-4	_	NN	_	_	33	PMOD	_	_
35	(	_	(	_	_	36	P	_	_
36	48,49	_	NN	_	_	34	PRN	_	_
37	)	_	)	_	_	36	P	_	_
38	.	_	.	_	_	12	P	_	_
		
1	In	_	IN	_	_	7	VMOD	_	_
2	addition	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	7	P	_	_
4	abundant	_	JJ	_	_	6	NMOD	_	_
5	IRF-4	_	NN	_	_	6	NMOD	_	_
6	expression	_	NN	_	_	7	VMOD	_	_
7	was	_	VBD	_	_	0	ROOT	_	_
8	found	_	VBN	_	_	7	VC	_	_
9	to	_	TO	_	_	8	VMOD	_	_
10	be	_	VB	_	_	9	IM	_	_
11	a	_	DT	_	_	12	NMOD	_	_
12	marker	_	NN	_	_	10	VMOD	_	_
13	for	_	IN	_	_	12	NMOD	_	_
14	various	_	JJ	_	_	15	NMOD	_	_
15	subsets	_	NNS	_	_	13	PMOD	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	lymphomas	_	NNS	_	_	16	PMOD	_	_
18	,	_	,	_	_	17	P	_	_
19	such	_	JJ	_	_	20	DEP	_	_
20	as	_	IN	_	_	17	COORD	_	_
21	diffuse	_	JJ	_	_	24	NMOD	_	_
22	large	_	JJ	_	_	24	NMOD	_	_
23	B-cell	_	NN	_	_	24	NMOD	_	_
24	lymphomas	_	NNS	_	_	20	CONJ	_	_
25	,	_	,	_	_	24	P	_	_
26	primary	_	JJ	_	_	28	NMOD	_	_
27	effusion	_	NN	_	_	28	NMOD	_	_
28	lymphoma	_	NN	_	_	24	COORD	_	_
29	,	_	,	_	_	28	P	_	_
30	and	_	CC	_	_	28	COORD	_	_
31	marginal	_	JJ	_	_	33	NMOD	_	_
32	zone	_	NN	_	_	33	NMOD	_	_
33	lymphoma	_	NN	_	_	35	COORD	_	_
34	,	_	,	_	_	30	P	_	_
35	and	_	CC	_	_	30	CONJ	_	_
36	adult	_	JJ	_	_	38	NMOD	_	_
37	T-cell	_	NN	_	_	38	NMOD	_	_
38	leukemia	_	NN	_	_	35	CONJ	_	_
39	(	_	(	_	_	40	P	_	_
40	11,31,50-52	_	NN	_	_	38	PRN	_	_
41	)	_	)	_	_	40	P	_	_
42	.	_	.	_	_	7	P	_	_
		
1	This	_	DT	_	_	2	VMOD	_	_
2	draws	_	VBZ	_	_	0	ROOT	_	_
3	a	_	DT	_	_	6	NMOD	_	_
4	more	_	RBR	_	_	5	AMOD	_	_
5	complex	_	JJ	_	_	6	NMOD	_	_
6	picture	_	NN	_	_	2	VMOD	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	role	_	NN	_	_	7	PMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	IRF-4	_	NN	_	_	10	PMOD	_	_
12	.	_	.	_	_	2	P	_	_
		
1	Down-regulation	_	NN	_	_	4	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	IRF-4	_	NN	_	_	2	PMOD	_	_
4	may	_	MD	_	_	0	ROOT	_	_
5	promote	_	VB	_	_	4	VC	_	_
6	leukemogenesis	_	NN	_	_	5	VMOD	_	_
7	in	_	IN	_	_	5	VMOD	_	_
8	myeloid	_	JJ	_	_	10	NMOD	_	_
9	cell	_	NN	_	_	10	NMOD	_	_
10	context	_	NN	_	_	7	PMOD	_	_
11	(	_	(	_	_	12	P	_	_
12	3	_	CD	_	_	10	PRN	_	_
13	)	_	)	_	_	12	P	_	_
14	,	_	,	_	_	10	P	_	_
15	which	_	WDT	_	_	16	VMOD	_	_
16	was	_	VBD	_	_	10	NMOD	_	_
17	recently	_	RB	_	_	16	VMOD	_	_
18	confirmed	_	VBN	_	_	16	VC	_	_
19	in	_	IN	_	_	18	VMOD	_	_
20	IRF-4-/-	_	JJ	_	_	24	NMOD	_	_
21	ICSBP-/-	_	JJ	_	_	24	NMOD	_	_
22	double	_	JJ	_	_	24	NMOD	_	_
23	knock-out	_	JJ	_	_	24	NMOD	_	_
24	mice	_	NNS	_	_	19	PMOD	_	_
25	(	_	(	_	_	26	P	_	_
26	53	_	CD	_	_	24	PRN	_	_
27	)	_	)	_	_	26	P	_	_
28	,	_	,	_	_	16	P	_	_
29	while	_	IN	_	_	16	VMOD	_	_
30	IRF-4	_	NN	_	_	31	NMOD	_	_
31	up-regulation	_	NN	_	_	32	VMOD	_	_
32	may	_	MD	_	_	29	SUB	_	_
33	induce	_	VB	_	_	32	VC	_	_
34	a	_	DT	_	_	36	NMOD	_	_
35	growth	_	NN	_	_	36	NMOD	_	_
36	advantage	_	NN	_	_	33	VMOD	_	_
37	in	_	IN	_	_	33	VMOD	_	_
38	lymphomas	_	NNS	_	_	37	PMOD	_	_
39	or	_	CC	_	_	38	COORD	_	_
40	MM	_	NN	_	_	39	CONJ	_	_
41	(	_	(	_	_	40	P	_	_
42	48	_	CD	_	_	40	NMOD	_	_
43	)	_	)	_	_	40	P	_	_
44	.	_	.	_	_	4	P	_	_
		
1	Taken	_	VBN	_	_	6	VMOD	_	_
2	together	_	RB	_	_	1	VMOD	_	_
3	,	_	,	_	_	6	P	_	_
4	our	_	PRP$	_	_	5	NMOD	_	_
5	data	_	NNS	_	_	6	VMOD	_	_
6	suggest	_	VBP	_	_	0	ROOT	_	_
7	that	_	IN	_	_	6	VMOD	_	_
8	IRF-4	_	NN	_	_	10	NMOD	_	_
9	promoter	_	NN	_	_	10	NMOD	_	_
10	methylation	_	NN	_	_	11	VMOD	_	_
11	regulates	_	VBZ	_	_	7	SUB	_	_
12	IRF-4	_	NN	_	_	13	NMOD	_	_
13	expression	_	NN	_	_	11	VMOD	_	_
14	,	_	,	_	_	7	P	_	_
15	and	_	CC	_	_	7	COORD	_	_
16	that	_	IN	_	_	15	CONJ	_	_
17	aberrant	_	JJ	_	_	18	NMOD	_	_
18	expression	_	NN	_	_	26	VMOD	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	IRF-4	_	NN	_	_	19	PMOD	_	_
21	in	_	IN	_	_	18	NMOD	_	_
22	certain	_	JJ	_	_	23	NMOD	_	_
23	types	_	NNS	_	_	21	PMOD	_	_
24	of	_	IN	_	_	23	NMOD	_	_
25	leukemia	_	NN	_	_	24	PMOD	_	_
26	may	_	MD	_	_	16	SUB	_	_
27	be	_	VB	_	_	26	VC	_	_
28	a	_	DT	_	_	29	NMOD	_	_
29	consequence	_	NN	_	_	27	VMOD	_	_
30	of	_	IN	_	_	29	NMOD	_	_
31	IRF-4	_	NN	_	_	33	NMOD	_	_
32	promoter	_	NN	_	_	33	NMOD	_	_
33	hypermethylation	_	NN	_	_	30	PMOD	_	_
34	.	_	.	_	_	6	P	_	_
		
